(Q33395708)

26 July 2017

title

Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer (English)

1 reference

26 July 2017

1 reference

1 reference

Akila Subramaniam

4

0 references

author name string

Janelle M Fauci

1

1 reference

26 July 2017

Jenny M Whitworth

2

1 reference

26 July 2017

Kellie E Schneider

3

1 reference

26 July 2017

Bin Zhang

5

1 reference

26 July 2017

Peter J Frederick

6

1 reference

26 July 2017

Larry C Kilgore

7

1 reference

26 July 2017

J Michael Straughn

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

11 June 2011

1 reference

26 July 2017

1 reference

26 July 2017

volume

122

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

532-535

1 reference

Stage IV ovarian cancer: impact of surgical debulking

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.023

10.1016/J.YGYNO.2011.05.023

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference